The Technion’s story has been intertwined with Israel’s for more than a century, from laying the foundations for a new nation to shaping its future.
Step inside Israeli innovation at the David and Janet Polak Visitors Center. Experience our 360° immersive movie and tech exhibition. Open to individuals and groups.
Learn MoreAs Seen in Calcalistech.com
“For millions living with Inflammatory Bowel Diseases (IBD), such as Crohn’s disease and ulcerative colitis (UC), every flare is a painful reminder of how little control they have over their lives. Flare-ups are unpredictable, debilitating, and costly,” said NimBio. The company has identified a clear challenge: a lack of time and actionable alerts for chronic inflammatory conditions.
“But early detection changes everything: If we could spot inflammation earlier, we could reduce flare-related hospitalizations by up to 50%, saving an estimated $5 billion annually, even with conservative assumptions,” the company added.
NimBio has developed a non-invasive Inflammometer™ technology that can be part of everyday devices like smartwatches or fitness bands. With AI-powered, non-invasive technology, it can detect the early signs of inflammation in real time before a flare begins.
Inflammatory Bowel Diseases (IBD) strike without warning — at home, at work, in the middle of your life. Flares force emergency care, disrupt daily life, and drain quality of life. IBD leads to hundreds of thousands of hospitalizations each year — not because the disease is untreatable, but because we still can’t see the flare coming.
NimBio Co-founder and Chief Medical Officer is Technion Prof. Emeritus Yehuda Chowers.